Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC6216 | TC-I 15 |
| Potent α2β1 integrin inhibitor (IC50 values for the inhibition of human platelet adhesion to type I collagen are 12 and 715 nM for platelets under static conditions and under flow, respectively). Displays selectivity for α2β1 over αvβ3, α5β1, α6β1 and αIIbβ3 at concentrations exceeding 1000 nM. Reduces collagen IV production in mesangial cells. Active in vivo; prevents ferric chloride-induced clot formation in mice. | |
| BCC6219 | NCX 466 |
| Cyclooxygenase (COX)-inhibiting nitric oxide (NO) donor (CINOD). Inhibits COX-1 and COX-2 while releasing NO. Demonstrates higher efficacy than naproxen, its congener drug, in reducing levels of profibrotic cytokine transforming growth factor-β and oxidative stress in a mouse model of bleomycin-induced lung fibrosis. Orally available. | |
| BCC6220 | T16Ainh - A01 |
| Inhibitor of Ca2+-dependent Cl- channel (CaCC) transmembrane protein 16A (TMEM16A) (IC50 = 1.8 μM in A253 salivary gland epithelial cells). Inhibits EGF-induced increases in CaCC currents; blocks proliferation of tumor cells in vitro. | |
| BCC6223 | ACHP |
| IκB kinase inhibitor (IC50 values are 8.5 and 250 nM for IKKβ and IKKα respectively). Selective for IKKα and IKKβ over IKK3, Syk and MAPKKK4 (IC50 values are > 20 μM). Inhibits DNA binding activity of NF-κB. Blocks NF-κB pathway in multiple myeloma cell lines; induces cell growth arrest and apoptosis. | |
| BCC6225 | HI TOPK 032 |
| T-LAK-cell-originated protein kinase (TOPK) inhibitor; exhibits selectivity for TOPK over other MAPKK family members including ERK1, JNK1 and p38. Blocks proliferation of HCT116 colon cancer cells; suppresses tumor growth in a colon cancer xenograft model. Also inhibits Chk1 (IC50 = 9.6 μM). | |
| BCC6228 | TC HSD 21 |
| Potent 17β-hydroxysteroid dehydrogenase type 3 (17β-HSD3) inhibitor (IC50 values are 6 and 40 nM at human and mouse 17β-HSD3 respectively). Displays no activity at 17β-HSD1, 17β-HSD2, ERα, androgen receptors or glucocorticoid receptors. | |
| BCC6229 | LDV FITC |
| Fluorescent ligand that binds to the α4β1 integrin (VLA-4) with high affinity (Kd values are 0.3 nM and 12 nM for binding to U937 cells in the presence and absence of Mn2+ respectively). Used to detect VLA-4 affinity and conformational changes. | |
| BCC6233 | Deltorphin I |
| Potent δ-opioid receptor agonist (IC50 = 0.5 nM in human granulocytes). Exhibits a high rate of blood-brain barrier penetrance. | |
